NBY Earnings

NBY reported its FY2024Q3 earnings on 2024-11-07, showcasing a revenue of 2.00M against an estimate of 3.00M, resulting in a -7.01% surprise. The EPS was -0.6, surpassing the expected -0.28 by -114.29% . The stock experienced a -2.78% price change on the earnings day and a -1.39% change over the next five days, reflecting market reactions to the results.

Following NBY's FY2024Q3 earnings announcement on 2024-11-07, the stock price moved by -2.78% on the day of the release. Over the subsequent five days, it saw a -1.39% change. Historically, NBY's stock price tends to shift by an average of +0.25% in the 10 days leading up to earnings and +7.81% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NBY’s annual revenue to reach 3.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between NBY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NBY's stock price typically moves by +0.25% in the 10 days before its earnings and +7.81% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 3.00M.

The earnings call presents a mixed picture: slight revenue growth and improved margins are offset by significant net losses and challenges in the capital market. The Q&A reveals strategic shifts in marketing and reliance on partnerships, but lacks clarity on EU sales reporting. The absence of new R&D investments is offset by partnership-driven innovation. Despite cost reductions, the financial health remains strained. Without clear guidance or major positive catalysts, the stock reaction is likely to remain neutral.